This company has been marked as potentially delisted and may not be actively trading. Intensity Therapeutics (INTS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrendsBuy This Stock INTS vs. BDRX, COCH, HILS, DRIO, KALA, ESLA, EGRX, EYEN, SXTC, and MRNSShould you be buying Intensity Therapeutics stock or one of its competitors? The main competitors of Intensity Therapeutics include Biodexa Pharmaceuticals (BDRX), Envoy Medical (COCH), Hillstream BioPharma (HILS), DarioHealth (DRIO), KALA BIO (KALA), Estrella Immunopharma (ESLA), Eagle Pharmaceuticals (EGRX), Eyenovia (EYEN), China SXT Pharmaceuticals (SXTC), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "medical" sector. Intensity Therapeutics vs. Its Competitors Biodexa Pharmaceuticals Envoy Medical Hillstream BioPharma DarioHealth KALA BIO Estrella Immunopharma Eagle Pharmaceuticals Eyenovia China SXT Pharmaceuticals Marinus Pharmaceuticals Intensity Therapeutics (NASDAQ:INTS) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Do insiders & institutionals have more ownership in INTS or BDRX? 3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 17.1% of Intensity Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is INTS or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Intensity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intensity TherapeuticsN/A -527.85% -276.29% Biodexa Pharmaceuticals N/A N/A N/A Which has higher earnings and valuation, INTS or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than Intensity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntensity TherapeuticsN/AN/A-$16.27M-$1.07-0.28Biodexa Pharmaceuticals$470K67.33-$7.32MN/AN/A Which has more risk & volatility, INTS or BDRX? Intensity Therapeutics has a beta of 3.27, suggesting that its share price is 227% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Does the media favor INTS or BDRX? In the previous week, Intensity Therapeutics had 2 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 4 mentions for Intensity Therapeutics and 2 mentions for Biodexa Pharmaceuticals. Intensity Therapeutics' average media sentiment score of 1.89 beat Biodexa Pharmaceuticals' score of 0.39 indicating that Intensity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biodexa Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer INTS or BDRX? Intensity Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 2,742.81%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intensity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIntensity Therapeutics beats Biodexa Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Intensity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INTS vs. The Competition Export to ExcelMetricIntensity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.52M$66.29M$5.50B$9.02BDividend YieldN/AN/A5.38%4.10%P/E Ratio-0.28N/A27.5520.29Price / SalesN/AN/A389.87112.84Price / CashN/AN/A36.6357.47Price / Book1.570.958.075.68Net Income-$16.27M-$26.57M$3.17B$249.04M Intensity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INTSIntensity Therapeutics1.7971 of 5 stars$0.30-88.5%$8.50+2,742.8%-93.8%$7.52MN/A-0.282,021Positive NewsGap UpBDRXBiodexa Pharmaceuticals0.6214 of 5 stars$0.87+0.6%N/AN/A$31.79M$470K0.0020Upcoming EarningsCOCHEnvoy Medical2.8322 of 5 stars$1.49+4.9%$9.25+520.8%-32.4%$31.78M$212K-1.0834News CoverageHILSHillstream BioPharmaN/A$1.80+2.4%N/A-45.0%$31.73MN/A-2.501DRIODarioHealth1.4155 of 5 stars$0.71+6.0%$2.00+181.7%-41.0%$31.57M$27.04M-1.27200KALAKALA BIO3.5583 of 5 stars$4.84+1.7%$13.50+178.9%-22.4%$31.22M$3.89M-0.5930High Trading VolumeESLAEstrella Immunopharma2.2514 of 5 stars$0.86-10.3%$16.00+1,758.7%-19.7%$31.14MN/A-3.31N/APositive NewsGap DownEGRXEagle PharmaceuticalsN/A$2.36-18.6%N/A-45.5%$30.65M$257.55M0.00100Gap DownEYENEyenovia1.0692 of 5 stars$10.56+1.7%$2.00-81.1%-74.0%$30.41M$60K-0.1840Gap UpSXTCChina SXT Pharmaceuticals0.1529 of 5 stars$1.92+11.0%N/A-78.3%$30.39M$1.82M0.0090News CoverageMRNSMarinus Pharmaceuticals2.3853 of 5 stars$0.55-0.2%$3.92+613.3%-54.6%$30.32M$30.99M-0.22110 Related Companies and Tools Related Companies BDRX Competitors COCH Competitors HILS Competitors DRIO Competitors KALA Competitors ESLA Competitors EGRX Competitors EYEN Competitors SXTC Competitors MRNS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INTS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. dollar’s worst run in 52 yearsThe U.S. dollar just posted its worst 6-month stretch since 1973 — and Trump’s tariffs are taking the blame. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
